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Stroke is a multifactorial disease that may be associated with aberrant DNA methylation profiles. We investigated epigenetic
dysregulation for themethylenetetrahydrofolate reductase (MTHFR) gene among ischemic stroke patients. Cases and controls were
recruited after obtaining signed written informed consents following a screening process against the inclusion/exclusion criteria.
Serum vitamin profiles (folate, vitamin B
12
, and homocysteine) were determined using immunoassays. Methylation profiles for
CpGsA and B in theMTHFR gene were determined using a bisulfite-pyrosequencingmethod.Methylation ofMTHFR significantly
increased the susceptibility risk for ischemic stroke. In particular, CpG A outperformed CpG B in mediating serum folate and
vitamin B
12
levels to increase ischemic stroke susceptibility risks by 4.73-fold. However, both CpGs A and B were not associated
with serum homocysteine levels or ischemic stroke severity. CpG A is a potential epigenetic marker in mediating serum folate and
vitamin B
12
to contribute to ischemic stroke.
1. Introduction
Stroke is amultifactorial disease with 90% of cases being clas-
sified as ischemic stroke while hemorrhagic stroke makes up
the remainder [1]. Emerging lines of evidence have suggested
that aberrantDNAmethylationmay affect the vulnerability of
central nervous system injury responses following ischemia
[2, 3]. Dynamic interactions between DNA methylation and
gene expression of pleiotropic factor thrombospondin 1 are
associated with ischemic stroke [4]. DNA methylation of
GNAS cluster [5] and sodium-potassium-chloride cotrans-
porter types 1 and 2 [6] are associated with ischemic stroke.
Even thoughmethylenetetrahydrofolate reductase (MTHFR)
is actively involved in the generation of S-adenosylmethio-
nine for methylation processes, to date, its methylation
profiles have not been fully elucidated. Additionally, few data
are available on the interaction between the differential DNA
methylation profiles ofMTHFR following cerebral ischemia.
Castro et al. [7] demonstrated that hyperhomocysteinemia
(levels higher than 75𝜇mol/L) is associated with a 35%
reduction in DNA methylation and increases the risk for
atherosclerosis. This observation indicates that the increased
risk of ischemic stroke may be explained, in part, by the
effects of differential DNA methylation profiles on brain
vulnerability in response to ischemic injury [4]. Hence, it
is hypothesized that although the mechanisms underlying
an increased risk of ischemic stroke have not been fully
elucidated, differential MTHFR methylation profiles may
better explain the pathogenesis of ischemic stroke.Therefore,
in this study, we aim to investigate potential epigenetic dys-
regulation ofMTHFR gene among ischemic stroke patients.
2. Materials and Methods
This study was approved by the Institutional Ethics Review
Committee of Universiti Sains Malaysia (reference number
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Informed consent and screening against inclusion and exclusion criteria
CpG A
CpG B
Controls (n = 110) Cases (n = 297)
Controls (n = 49) Cases (n = 149)
Figure 1: An overview of the study design.
USMKK/PPP/JEPeM [231.1.(08)]) which complies with the
Declaration of Helsinki. Signed written informed consent
forms were obtained from each participant prior to their
enrollments following screening against the inclusion and
exclusion criteria. Cases were included if they were three
generations of Malays, who were between 18 and 70 years
old, who have shown occlusion, stenosis, and/or lesion on
brain imaging system (computerized tomography scan or
magnetic resonance imaging), and whose ischemic stroke
severity has been assessed based on Modified Rankin Scale.
Ischemic stroke patients were excluded if they participated in
any on-going clinical trial study, they have taken any form
of vitamins B supplementation six months prior to the study,
they have brain tumors or other forms of cancer, or brain
imaging has confirmed that patients suffer from intracerebral
hemorrhage. Three generations of Malays with the same
age group as cases with normal findings on medical history
and physical examination were included as controls subjects.
Healthy subjects who have positive family history of stroke,
who have taken any form of vitamins B supplementation six
months prior to the study, and who have medical illness that
requires treatments were excluded as control subjects. It is
important to note that positive association between CpG A
methylation and ischemic stroke is further confirmed by 149
cases and 49 controls from the same population, and they
are tested on CpG B (Figure 1). In addition, Modified Rankin
Scale has been used as the ischemic stroke assessment tools
because of the incomplete data of National Institute of Health
Stroke Scale in all of the cases.
Fasting blood samples (6mL) were collected in clot
activator gel tube (Becton Dickinson) for the determination
of serum vitamin profiles (serum homocysteine, folate, and
vitamin B
12
levels). Serum homocysteine levels were deter-
mined using fluorescence polarization immunoassay (Archi-
tect ci8200 Abbott, Illinois), while serum folate and vitamin
B
12
levels were determined using competitive immunoassay
of direct chemiluminescence technology (ADVIA Centaur
XP Immunoassay System, Siemens Healthcare). Venous
blood samples (2mL) were collected for DNA methylation
profiling. DNA extraction, bisulphite treatment, and PCR-
pyrosequencing were performed to determine methylation
levels of CpGs A and B (Loo et al., unpublished data).
Statistical analysis was conducted using the R package
version 3.0.3 (New Jersey, USA). The demographic char-
acteristics of the subjects were analyzed using 𝑡-tests for
continuous variables while chi-squared (𝜒2) test was used for
categorical variables. The distribution of serum vitamin pro-
files was investigated for normality using the Kolmogorov-
Smirnov test. Pearson correlation coefficient (𝑟) was used
to establish the correlation between methylation and serum
vitamin profiles followed by Bonferroni correction. Ischemic
stroke severity was defined using a Modified Rankin Scale.
Logistic regression models were used to estimate the odds
ratios (ORs) and 95% confidence intervals (CI) for determin-
ing possible high riskmethylation profiles for ischemic stroke
and its severity. Additionally, potential confounders such as
the age, genders, waist to stature, diabetes, hypertension,
hypercholesterolemia, heart diseases, smoking, coffee drink-
ing, tea drinking, and serum vitamin profiles were controlled
in multivariate analysis.
3. Results
Cases and controls demonstrated similar waist to stature, age,
and gender groupings (Table 1, all 𝑃 > 0.05). However, the
frequencies of diabetes, hypertension, hypercholesterolemia,
heart diseases, smoking, coffee drinking, and tea drinking
were significantly different when cases were compared with
controls (Table 1, all 𝑃 < 0.05). Correlation analysis demon-
strated that the methylation levels in CpG A were positively
correlated with serum folate (𝑟 = 0.106, 𝑃 = 0.032) and
vitamin B
12
(𝑟 = 0.114, 𝑃 = 0.022) levels but not with those
in CpG B. Methylation profiles in both CpGs A and B were
not significantly correlated with serum homocysteine levels.
Followingmultivariate adjustment, CpGAmethylation levels
were shown to confer a significantly higher risk (by 4.73-fold)
for ischemic stroke (95% CI: 2.56–8.75, 𝑃 < 0.001) (Table 2).
The susceptibility risk for CpG B levels was, however, not
significantly associated with the risks for ischemic stroke
(Table 2). In addition, CpG levels were not significantly asso-
ciated with ischemic stroke severity following multivariate
analysis (Table 3, 𝑃 > 0.05).
4. Discussion
To our knowledge, this is the first study to investigateMTHFR
methylation profiles among Asian ischemic stroke patients.
Even though there is some support for a role of epigenetics in
ischemic stroke risk [2, 7, 8], most studies [2, 8] have focused
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Table 1: Demographic characteristics of study subjects.
Parameters CpG A CpG B
Controls (𝑛 = 110) Cases (𝑛 = 297) Controls (𝑛 = 49) Cases (𝑛 = 149)
Age (years) 52.74 ± 7.69 52.62 ± 8.83 51.12 ± 7.29 52.08 ± 8.21
Gender (male : female) 1.16 1.83 0.96 1.48
Waist to stature 0.52 ± 0.93 0.60 ± 1.36 0.51 ± 0.11 0.52 ± 0.11
Diabetes (%) 29.09 54.88∗∗ 24.49 65.10∗∗
Hypertension (%) 9.09 76.77∗∗ 4.08 86.58∗∗
Hypercholesterolemia (%) 9.09 71.38∗∗ 6.12 71.14∗∗
Heart diseases (%) 11.82 23.91∗ 2.04 20.13∗
Smoking (%) 29.09 43.43∗∗ 24.49 43.62∗
Coffee drinking (%) 51.82 67.34∗ 44.90 64.43∗
Tea drinking (%) 59.09 82.15∗∗ 63.27 85.91∗
Values are the mean ± standard deviation from 𝑡-test for continuous variables and 𝜒2 test for categorical variables. ∗ and ∗∗ denote 𝑃 < 0.05 and 𝑃 < 0.001,
respectively.
Table 2: Susceptible risk of DNA methylation on ischemic stroke.
CpGs Crude Adjusted
𝛽 95% CI 𝑃 value 𝛽 95% CI 𝑃 valuea
A 3.85 2.72–5.45 <0.001 4.73 2.56–8.75 <0.001
B 1.38 1.08–1.77 0.011 0.90 0.56–1.45 0.975
aMultivariate analysis adjusted for age, genders, waist to stature, diabetes, hypertension, hypercholesterolemia, heart diseases, smoking, drinking coffee and/or
tea, and serum vitamin profiles.
Table 3: Influence of DNA methylation on ischemic stroke severity.
CpGs Crude Adjusted
𝛽 95% CI 𝑃 value 𝛽 95% CI 𝑃 valuea
A −0.09 −0.15 to 0.13 0.601 −0.02 −0.16 to 0.12 0.743
B 0.02 −0.25 to 0.31 0.757 0.02 −0.71 to 0.85 0.946
aMultivariate analysis adjusted for age, genders, waist to stature, diabetes, hypertension, hypercholesterolemia, heart diseases, smoking, drinking coffee and/or
tea, and serum vitamin profiles.
on increased susceptibility risk of ischemic stroke and long
interspersed element-1methylation. Similar tomost epidemi-
ological studies utilizing DNA from peripheral blood cells [8,
9], our study supports the notion that DNA is an informative
determinant for epigenetic variation especially when brain
cells are inaccessible [9]. We demonstrated that CpG A but
not CpG B methylation levels were significantly associated
with increased susceptibility risk for ischemic stroke.
MTHFR methylation profiles at CpG A were associated
with serum folate and vitamin B
12
levels and also with higher
risks of ischemic stroke when compared to CpG B. Computa-
tional biology analyses have indicated that low density lysine
4 histoneH3 trimethylation and incomplete RNApolymerase
II in CpG B [10] may affect the transcriptional activity of
MTHFR. Increased lysine 4 histone H3 methylation is an
epigenetic mark for euchromatin, often accompanied by the
presence of RNA polymerase II to act as an active promoter
[11].
Several studies have demonstrated a link between vitamin
profiles and DNA methylation indicating the pertinent role
of one carbon metabolism in modulating DNA methylation
[3, 9]. One carbon metabolism has been reported to be the
main channel for methyl group donation at cellular levels
[12] where a depletion of vitamin B
12
or folate can reduce
the bioavailability of S-adenosylmethionine [3]. Moreover,
decreased bioavailability of S-adenosylmethionine can ham-
per the genome wide methylation process [2] and favor the
reduction of lysine 4 of histone H3 methylation [3].
However, we have not established any correlation of
MTHFR methylation with serum homocysteine levels sug-
gesting that (1) an intergenic methylation ofMTHFRmay not
play a major role in affecting the serum homocysteine levels
and (2) serum homocysteine levels may not be an essential
proxy for gene expression changes. Another possible explana-
tion for the lack of correlation betweenMTHFRmethylation
and serum homocysteine levels could be partly due to the
fact that serumS-adenosylhomocysteine levelsmay be amore
sensitive marker as compared to serum homocysteine levels
in determining the bioavailability of S-adenosylmethionine
[13]. In fact, the nonsignificant correlation may also explain
the nonsignificant correlation betweenMTHFR methylation
and ischemic stroke severity.This is supported by the fact that
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homocysteine is actively involved in oxidative stress events
which can affect vascular structure [14], thus worsening
ischemic stroke severity [4, 15].
A recent report on the association between hemimethy-
lated MTHFR gene and silenced MTHFR gene expression
among end-stage renal disease patients [16] has further
suggested a significant role of MTHFR promoter methyla-
tion on its gene expression levels. Therefore, future studies
which investigate the effects ofMTHFRmethylation on gene
expression changes are warranted for a better understanding
of the epigenetic mechanisms ofMTHFR inmediating serum
vitamin profiles to contribute to ischemic stroke.
5. Conclusion
Methylation of MTHFR significantly increases susceptibility
risk for ischemic stroke but does not affect ischemic stroke
severity. MTHFR CpG A outperforms CpG B in mediating
folate and vitamin B
12
levels to increase ischemic stroke sus-
ceptibility by 4.73-fold; however, neither CpG was correlated
with serum homocysteine levels.
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